RALEIGH, N.C., May 17, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce that for the third consecutive year it was recognized as the Clinical Research Company [...]
See the latest interactions from our social media
No worries if you can't see us in person at #DIA2016 -- we've got first hand video for you right now.
Read the latest updates from our PR department
RALEIGH, N.C., May 02, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that certain of its stockholders (the “Selling Stockholders”), intend to [...]
$372.3 million of service revenue in the first quarter; 13.0% constant currency growth compared to the first quarter of 2015 First quarter GAAP Net Loss of $16.0 million or $0.27 per diluted share, [...]
Explore the latest resources uploaded to our media library
Brought to you by PRA Health Sciences. A Bi-Weekly Industry Watch Newsletter
PRA recently performed a feasibility study to identify investigators who see patients with a rare neuromuscular autoimmune disease and who have the capability to perform a Phase II clinical trial.
PRA Health Sciences provides our clients with innovative solutions for CNS (neurology, psychiatry, and pain) drug development. Our work spans from early phase development to NDA and MAA submissions...
A large pharmaceutical client selected PRA to conduct 2 Phase III epilepsy studies in India, Eastern and Western Europe, and Australia. PRA’s project teams surpassed recruitment goals and achieved timely site activations despite administrative delays and tough competition for volunteers.
Find out what's happening next on PRA's event schedule
DIA 2016 is the largest global interdisciplinary event that brings together key thought leaders and innovators from industry, academia, regulatory and government agencies, health, patient, and philanthropic organizations from around the globe – and across all disciplines involved in the discovery, development, and life cycle management of health care products. The goal of the DIA […]
The Land o’Lakes conference seeks to provide an educational forum to discuss issues and applications associated with the analysis of overall approaches associated with Biomarker validation, stability and the associated regulatory concerns that come from this growing area of research. Speakers will present information from new and innovative areas of bioanalysis of biologic therapeutics, small […]
The Nordic region is proud to host some of the world’s most innovative biotech, medtech and pharma companies. It also has the 12th strongest economy, making it the perfect place to invest. Set in the idyllic city of Stockholm, the conference offers conference sessions, panel discussions, company presentations, exhibition, face-to-face meetings and unique receptions, providing […]